2C-P

hypertension, coronary artery disease, heart failure, arrhythmia

Tachycardia and hypertension are consistently reported in 2C-P clinical cases. Individuals with pre-existing cardiovascular conditions, uncontrolled hypertension, or structural heart disease face elevated risk, particularly given the prolonged sympathomimetic activation (10-20 hours).

Long QT syndrome (congenital or drug-induced) is an absolute contraindication due to the combined serotonergic and sympathomimetic effects of 2C-P over a prolonged duration.

Seizure disorders represent a relative contraindication. The related compound 2C-I has been associated with seizures in a published case report. Serotonergic activity may lower seizure threshold in predisposed individuals.

Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder) is an absolute contraindication. 5-HT₂A agonism may trigger psychotic episodes in predisposed individuals, and the 10-20 hour duration of 2C-P extends the risk window substantially.

Bipolar disorder (type I or II) is an absolute contraindication. Risk of manic episode precipitation is established across the serotonergic psychedelic class. The prolonged duration of 2C-P increases the window for destabilization.

Significant hepatic impairment may alter 2C-P metabolism and clearance, potentially increasing plasma levels and prolonging effects. Given the steep dose-response curve, even modest increases in exposure could shift effects from tolerable to dangerous.

Pregnancy is an absolute contraindication. No reproductive or teratogenicity data exist for 2C-P. 5-HT₂A receptor signaling is involved in neurodevelopmental processes, and the cardiovascular stress (tachycardia, hypertension) poses additional risk.